Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor

Next Previous
X
Search
Trial Profile

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 12 Nov 2017 Results of an investigator-initiated post hoc analysis (n=237) assessing an alternative cut-off for definition of partial response able to predict clinical benefit from treatment with sunitinib in patients diagnosed with pancreatic neuroendocrine tumours using individual data of patients from the phase II [NCT00056693] and phase III [NCT00428597] trials, published in the British Journal of Cancer.
    • 03 Jun 2008 Status changed from active, no longer recruiting to completed.
    • 18 Sep 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top